Effect of human gastrin-17 with and without acid suppression on human esophageal motility.
The putative role of gastrin for the regulation of esophageal motility is a matter of debate. Accordingly it was the aim of this study a) to examine if physiological postprandial plasma levels of human gastrin-17 (hG-17) can affect esophageal motility, especially the pressure of the lower esophageal sphincter (LESP), and b) to assess the contribution of augmented acid secretion during gastrin infusion. In a first series of experiments postprandial plasma gastrin levels were determined in 8 healthy volunteers following the ingestion of a mixed meal. Gastrin rose from a baseline of 21 +/- 2 pg/ml to 67 +/- 8 pg/ml and returned almost to basal levels within 120 minutes. In a second experimental series the effect of i.v. synthetic human gastrin-17 (hG-17) was studied in 17 volunteers. At a lower dose of 0.75 ng/kg/min hG-17 increased plasma gastrin to 62 +/- 7 pg/ml while a higher dose of 1.5 ng/kg min elicited a supraphysiological increase to 119 +/- 11 pg/ml. Infusion of hG-17 caused a significant increase of the LESP from 19.0 to 25.8 mmHg (p < 0.05, low dose) and from 18.5 mmHg to 23.3 mmHg (p < 0.05, high dose) when compared to the effect of i.v. saline. To exclude effects of augmented acid secretion during hG-17 infusion the experiments were repeated after complete blockade of acid secretion with famotidine 40 mg i.v. After famotidine pretreatment hG-17 caused a similar increase of LESP from 20.1 to 25.9 mmHg (low dose) and from 19.9 to 24.1 mmHg (high dose).(ABSTRACT TRUNCATED AT 250 WORDS)
Allescher
H D
HD
II. Medizinische Klinik und Poliklinik, TU München, Germany.
Stoschus
B
B
Wünsch
E
E
Schusdziarra
V
V
Classen
M
M
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004943:Esophagogastric Junction / Q000187:drug effects; D004947:Esophagus / Q000187:drug effects*; D015738:Famotidine / Q000494:pharmacology; D005260:Female; D005744:Gastric Acid / Q000502:physiology*; D005755:Gastrins / Q000097:blood / Q000494:pharmacology*; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D006728:Hormones / Q000494:pharmacology*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D010528:Peristalsis / Q000187:drug effects*
D005755:Gastrins; D006635:Histamine H2 Antagonists; D006728:Hormones; D015738:Famotidine; C013550:gastrin 17